Publicaciones en las que colabora con Juan Francisco Navarro González (56)

2024

  1. FGF23 as a Potential Pathophysiological Factor in Peripheral Arterial Disease Associated with Chronic Kidney Disease

    International Journal of Molecular Sciences, Vol. 25, Núm. 10

2022

  1. Electronic Patient-Reported Outcomes in Nephrology: Focus on Hemodialysis

    Journal of Clinical Medicine, Vol. 11, Núm. 3

  2. Klotho expression in peripheral blood circulating cells is associated with vascular and systemic inflammation in atherosclerotic vascular disease

    Scientific Reports, Vol. 12, Núm. 1

  3. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

  4. Silver jubilee: 25 years of the first demonstration of the direct effect of phosphate on the parathyroid cell

    Nefrologia, Vol. 42, Núm. 6, pp. 645-655

2021

  1. Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced kidney injury

    American journal of physiology. Renal physiology, Vol. 320, Núm. 4, pp. F628-F643

2020

  1. Inflammatory targets in diabetic nephropathy

    Journal of Clinical Medicine, Vol. 9, Núm. 2

2019

  1. Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

    Clinical Kidney Journal, Vol. 12, Núm. 3, pp. 313-321

  2. Fibroblast growth factor 23 expression in human calcified vascular tissues

    Aging, Vol. 11, Núm. 18, pp. 7899-7913

  3. Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizons

    Journal of Clinical Medicine, Vol. 8, Núm. 3

2017

  1. Anti-inflammatory profile of paricalcitol in kidney transplant recipients

    Nefrologia, Vol. 37, Núm. 6, pp. 622-629

  2. Soluble levels and endogenous vascular gene expression of KLOTHO are related to inflammation in human atherosclerotic disease

    Clinical Science, Vol. 131, Núm. 21, pp. 2601-2609

2016

  1. Urinary Clara Cell Protein in Kidney Transplant Patients: A Preliminary Study

    Transplantation Proceedings, Vol. 48, Núm. 9, pp. 2884-2887

2015

  1. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial

    Journal of the American Society of Nephrology, Vol. 26, Núm. 1, pp. 220-229

2012

  1. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study

    BMC Nephrology, Vol. 13, Núm. 1

2010

  1. Erdheim-Chester disease as cause of end-stage renal failure: A case report and review of the literature

    International Urology and Nephrology, Vol. 42, Núm. 4, pp. 1107-1112

  2. Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease

    American Journal of Respiratory and Critical Care Medicine, Vol. 182, Núm. 8, pp. 1004-1010

2007

  1. Implicaciones de la inflamación en la lesión renal secundaria a la diabetes mellitus

    Implicaciones de la inflamación en la lesión renal secundaria a la diabetes mellitus

2006

  1. Trombocitopenia inducida por heparina en hemodiálisis. Presentación de un caso y revisión de la literatura

    Nefrologia, Vol. 26, Núm. 6, pp. 734-737

2003

  1. Effects of pentoxifylline administration on urinary N-acetyl-β-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomized study

    American Journal of Kidney Diseases, Vol. 42, Núm. 2, pp. 264-270